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Response of breast carcinoma to endocrine therapy predicted using
immunostained pelleted fine needle aspirates
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'Department ofHistopathology, UMDS, St Thomas Hospital, London SE] 7EH; and Department ofSurgery, William Harvey
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Summary Fine needle aspirates from 82 patients with breast carcinoma were fixed in methacarn, double
embedded in agar or gelatin, and then in paraffin wax. Sequential sections were stained with monoclonal
antibodies to the oestrogen receptor-related protein P29 (antibody D5), carcinoembryonic antigen (CEA),
epithelial membrane antigen (EMA) and cytokeratin (CAM 5.2). Sixty-one of 82 (74%) aspirates provided
sections suitable for immunostaining. Twenty-six (43%) were D5 positive, 23 (38%) CEA positive, 59 (97%)
EMA positive, and 54 (89%) CAM 5.2 positive. Twenty-six of these patients were treated with some form of
endocrine therapy. Twelve (46%) showed positive staining for D5. Eleven (92%) of the 12 D5-positive patients
responded or had static disease, and 8% progressed. Of the 14 D5-negative tumours 43% responded or
remained static, and 57% progressed. The difference in response between the D5-positive and the D5-negative
tumours was significant (P<0.05, Fisher's exact test). There was no correlation between staining for CEA,
EMA or cytokeratin and response to endocrine therapy.
Biochemical estimation of the oestrogen receptor (ER) con-
tent of breast tumours is a well established predictor both of
response to endocrine therapy and of survival (Seibert &
Lippman, 1982; Witliff, 1984). There are several difficulties
associated with the biochemical assay including the need for
rapidly frozen material, and the quantity of tissue required,
especially when the tumour is small. Immunocytochemical
techniques, on the other hand, can be carried out on small
tissue sections or on smears. Monoclonal antibodies directed
against the oestrogen receptor (King & Greene, 1984) and
related proteins (King et al., 1985) are now available. The
mouse monoclonal antibody D5 directed against the oest-
rogen receptor-related protein, P29, can be used to immuno-
stain paraffin embedded material fixed in alcohol or in
methacarn, without enzyme predigestion (King et al., 1985;
Cano et al., 1986). The rat monoclonal antibody directed
against the nuclear oestrogen receptor protein (ERICA
antibody, Abbott Laboratories, Chicago, USA) requires
either fresh unfixed tissue or DNAse pretreatment of paraffin
embedded sections (Shintaku & Said, 1987).
There have been reports of the predictive value of staining
with other antibodies. It has been stated that the presence of
carcinoembryonic antigen (CEA) (Shousha et al., 1979;
Walker, 1980), and the intensity of staining for a material
similar to the large glycoprotein, termed epithelial membrane
antigen (EMA) (Heyderman et al., 1985), using monoclonal
antibodies HMFG1 (Wilkinson et al., 1984) and NCRC-I1
(Ellis et al., 1987), is predictive of outcome. Markers such as
EMA and cytokeratin (antibody CAM 5.2; Makin et al.,
1984) are of possible value for the distinction of breast
epithelial cells from stroma.
Although smears prepared from fine needle aspirates have
been used for the immunocytochemical localisation of oest-
rogen receptor and related proteins (Flowers et al., 1986;
Cavailles et al., 1987; Coombes et al., 1987), these prepara-
tions are unsuitable for the comparative demonstration of
multiple markers due to the variation in number of cells per
slide, and limitations in the number of slides that can be
prepared from a single aspirate. An alternative approach has
been to expel the aspirates into tissue culture medium, and
make cytospin preparations on polylysine coated slides
(Hawkins et al., 1988). However, since the cells are not fixed
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until after the cytospins are made, the aspirates cannot be
stored in medium at room temperature.
The aim of this study was to evaluate a quick and easy
method suitable for a busy outpatient clinic, which would
allow samples to be sent through the post for further process-
ing, with no requirement for any low temperature storage.
We developed a method whereby aspirates were immediately
expelled into methacarn fixative, double embedded originally
in 4% agar and now more conveniently in 5% gelatin, and
then into paraffix wax. At least 10 sections were cut from
each block (Heyderman & Brown, 1986), and several anti-
gens were evaluated in sequential sections of the same as-
pirate.
This paper reports the results of a pilot study carried out
to correlate the results of immunostaining with response to
Tamoxifen or other endocrine therapy.
Patients and methods
Clinical material
Fine needle aspirates from 82 patients with primary or recur-
rent breast carcinomas were used. Patients with early breast
cancer were generally treated by surgery except for those
over the age of 70, who were randomised into a trial in
which one group received Tamoxifen alone, and the other
surgery plus Tamoxifen. Patients with recurrent or advanced
cancer mainly received Tamoxifen as their primary endocrine
therapy.
Following fine needle breast aspiration, 26 patients were
treated by Tamoxifen or other endocrine therapy (megestrol
acetate, aminoglutethamide or prednisolone), and response
was correlated with the immunocytochemical detection of the
oestrogen receptor-related protein P29. Eight patients had
early breast cancer (stages I or II, age 70-85, median 74
years), and 18 patients had advanced breast cancer (stages III
or IV, age 44-92, median 75 years). Tumour response was
assessed using the UICC criteria (Hayward et al., 1977) as:
complete response, with disappearance of the tumour; paitial
response, with at least 50% reduction in area maintained for
at least one month; no change, with less than 50% reduction
in area; or progressive disease, with greater than 25% in-
crease in area.
Methods
The breast aspirates were expelled into 1.5 ml polypropylene
microcentrifuge tubes containing methacarn (methanol 60%;
chloroform 30%; glacial acetic acid 10%), and sent by post
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from the William Harvey Hospital, Kent, to St Thomas
Hospital, London, and processed up to six months after
receipt. The double embedding method used was a modi-
fication of that previously published (Heyderman & Brown,
1986). The aspirates were pelleted by centrifugation, washed
and resuspended in absolute ethanol, and then in distilled
water. The supernatant was removed and replaced with 5%
gelatin or 4% agar made up in distilled water (approximately
300 it per tube). The pellets were gently mixed by shaking,
and allowed to set at 4°C. Once set, they were dehydrated in
graded alcohols, removed from the tube, and excess gelatin
or agar trimmed away. The pellets were cleared in xylene and
immersed in paraffin wax overnight at 60°C to ensure full
wax penetration. They were then embedded in paraffin wax
in Tissue-Tek cassettes. Sequential 41im sections were de-
waxed, an H & E prepared, and unstained sections immuno-
stained using an indirect immunoperoxidase technique (Hey-
derman, 1986).
The mouse monoclonal antibodies used were those to the
oestrogen receptor related protein P29 (antibody D5; diluted
1:60; Amersham International plc, Bucks.), CEA (ascites
diluted 1:250; Amersham International plc, Bucks.), EMA
(diluted 1:40; Dakopatts, Bucks.), and cytokeratin (antibody
CAM 5.2; diluted 1:2; Becton Dickinson, Oxford). The sec-
ond antibody was an affinity purified sheep anti-mouse per-
oxidase conjugate (Amersham International plc). For sections
stained with antibodies to CEA, EMA and CAM 5.2, inhibi-
tion of endogenous peroxidase was carried out using a
sequence of 6% hydrogen peroxide, 2.5% periodic acid and
0.02% potassium borohydride. Staining with D5 is somewhat
diminished by periodic acid treatment (Roe et al., 1986), so
only 6% hydrogen peroxide was used to inhibit endogenous
peroxidase with this antibody. It was therefore possible that
inhibition might not have been as complete as with the full
blocking method.
The positive control for D5 was a paraffin-embedded
~~~~~~~- ,
Figure 1 H & E preparation of a breast pellet fixed in metha-
carn showing clumps of viable tumour cells with some necrotic
fragments (arrowed), x 140.
Figure 3 The same pellet stained with the D5 antibody to the
oestrogen receptor-related protein, P29. Most of the cells are
positive, x 330.
methacarn-fixed section of normal skin, which shows positive
staining of the granular layer of the epidermis and skin
adnexae, and weak staining of smooth muscle of blood
vessels and erector pili. A formalin fixed carcinoma of the
colon was used for CEA, a carcinoma of the breast for
EMA, and a papillary carcinoma of the thyroid for
CAM 5.2. The negative control antibody was PASE/4LJ, an
IgG1 mouse monoclonal antibody to prostatic acid phos-
phatase, which can be used to stain formalin or methacarn-
fixed tissue of prostatic origin and does not stain benign or
malignant breast tissue (Haines et al., 1987).
Results
Sixty-one (74%) of the 82 original pellets were assessable.
Sixty-three (77%) of the 82 haematoxylin and eosin stained
sections contained tumour (Figures 1 and 2). However, when
five sections of each block were immunostained, 310/315
(98%) of the immunostained sections contained tumour cells.
The five sections that no longer had any tumour came from
two of the pellets, so these two cases were excluded from the
study.
Where there were plenty of cells, the cytological diagnosis
of malignancy was as easy or easier than in smears, and there
were often vestiges of acinar architecture. In case of doubt
about the diagnosis, it was possible to examine further sec-
tions of the pellet. Methacarn fixation caused the cells to
swell, and when the number of cells was small, cytological
diagnosis was more difficult, but not more so than with a
scanty smear.
Twenty-six of the pellets (43%) contained cells positive for
D5 (Figure 3). Twenty-three (38%) were positive for CEA
(Figure 4), 59 (97%) for EMA and 54 (89%) for cytokeratin
(CAM 5.2). The number of positive cells varied from occas-
ional positive cells (Figure 4) to the majority (Figure 3).
Figure 2 Higher power of one of the larger clumps showing
good cytological preservation, x 330.
Figure 4 While most cells in this pellet were positive for D5,
EMA and cytokeratin, only a few cells were positive for CEA,
and in the field shown they are arranged in acini (arrowed). At
this level in the paraffin block the shape of the clump has begun
to change, but numerous tumour cells are still present, x 330.632 E. HEYDERMAN et al.
Because of the relatively small number of cells in some of the
pellets, and the inevitable sampling error in fine needle as-
piration, the cases were not subclassified further by intensity
of staining or the proportion of cells positive for each mar-
ker. Of the 26 patients treated with endocrine therapy, 12
(46%) were D5 positive and 14 (64%) were D5 negative.
Eleven of the 12 (92%) D5 positive tumours responded or
had static disease on endocrine therapy, with only one (8%)
progressing. Of the 14 D5 negative tumours, six responded or
remained static (43%), while eight (57%) progressed (Table
I). The difference between the response of D5 positive and
negative tumours was significant (P<0.05, Fisher's exact
test).
None of the D5 positive pellets contained more than 80%
positive tumour cells, and several contained as few as 5%,
including responders. However, all of the D5 negative pellets
from tumours which responded to endocrine manipulation or
remained static contained at least 250 cells per section, mak-
ing a false negative due to inadequate cell number less likely.
There was no correlation between CEA positivity and D5
staining, nor between staining for CEA and response to
therapy (Tables II and III). EMA was useful in general as an
indicator of the presence of epithelial cells, although two
specimens contained unequivocal tumour cells that were
EMA negative. They were, however, cytokeratin positive,
helping to confirm the epithelial nature of the cells. One
responded to endocrine therapy and the other progressed.
The vast majority of the cells in the other pellets were
strongly positive for EMA, so no assessment of either the
intensity or the distribution of staining for EMA was attemp-
ted.
Two of the seven CAM 5.2 negative tumours were treated
by hormone therapy. Both were unresponsive.
All of the breast pellets were negative when immuno-
stained with the control monoclonal antibody to prostatic
acid phosphatase, PASE/4LJ; the control block of hyperplas-
tic benign prostatic tissue was strongly positive with this
antibody.
Table I Correlation of response to endocrine therapy and positive
indirect immunoperoxidase stain for oestrogen receptor-related protein
P29 (antibody D5)
D5 + % D5- %
Responded 8 4
(CR + PR) . 92% . 43%
Static 3 2)
Progressed 1 8% 8 57%
Total 12 (46%) 14 (54%)
Response + static vs progressed (P<0.05, Fisher's exact test).
Table II Indirect immunoperoxidase stain for CEA, and for
oestrogen receptor-related protein P29, antibody D5
D5 + % D5- %
CEA+ 11 42% 12 34%
CEA- 15 58% 23 66%
Total 26 (43%) 35 (57%)
P = not significant, Fisher's exact test.
Table III Response to endocrine therapy, and indirect immunoperox-
idase stain for CEA
CEA + % CEA- %
Responded 7 6
> 73% > 55%
Static 4 J
Progressed 4 27% 5 45%
Total 15 (58%) 11 (42%)
Response + static vs progressed (P = not significant, Fisher's exact
test).
Discussion
In this pilot study, positive staining with antibody D5 to the
oestrogen receptor-related protein P29 proved a good predic-
tor of the success of endocrine therapy: 92% of the patients
whose aspirates were D5 positive and who had endocrine
therapy responded or had static disease, 8% progressed.
Absence of staining predicted progressive disease in 57%,
and 43% of the D5 negative tumours responded or remained
static (P<0.05 Fisher's exact test). However, since in some
pellets as few as 5% of the cells were positive, there may
have been false negatives due to sampling error.
The prediction of response to endocrine therapy presented
here is comparable to what would be expected using a con-
ventional biochemical assay for oestrogen receptor (Witliff,
1984). An immunocytochemical study of breast smears using
the ERICA antibody to nuclear oestrogen receptor on breast
smears showed results similar to ours (Coombes et al., 1987).
In that study, 14 primary, 10 recurrent and 36 secondary
tumours were examined. Responsive and static tumours
formed 92% of their ERICA positives and 44% of negatives.
In a more recent study using the same antibody on cytospin
preparations, very good correlation was shown between posi-
tivity and response to Tamoxifen (Gaskell et al., 1989). In
that study, the number of positive cells, rather than the
intensity of staining, was of predictive value. Because of the
small number of cases in this study, we scored the slides as
positive or negative, and so may have lost the extra inform-
ation given by counting the proportion of D5 positive cells.
While our results are statistically significant, the numbers
are small, and we do not yet know whether D5 positivity is
correlated with length of survival or with duration of respon-
se. Studies comparing biochemical and immunocytochemical
assays of frozen sections of breast carcinoma using the anti-
body to the oestrogen receptor and the D5 antibody have
shown a poor correlation between D5 and oestrogen receptor
biochemical or immunohistochemical assay (Giri et al., 1987).
However, as previously suggested by Giri et al., it is possible
that the presence of the P29 antigen recognised by D5 is an
independent predictor of response to Tamoxifen or other
endocrine manipulation.
The positivity for CEA (38%) is comparable with the
results of previous studies (Shousha et al., 1979; Walker,
1980), but staining for CEA was not predictive of response to
endocrine therapy. We are continuing clinical follow-up to
determine whether positive staining will predict time to recur-
rence of primary tumours or length of survival.
The demonstration of EMA in all but two of the pellets
indicates the value of this antibody in suggesting the epi-
thelial nature of some of the more traumatised preparations.
Its localisation does not, however, distinguish between benign
and malignant cells. The two EMA negative preparations
may represent sampling error, since in any breast tumour
there is heterogeneity of staining for EMA, as well as for
most other markers. Alternatively, they could represent as-
pirates from the first two EMA-negative breast tumours we
have seen.
It has been suggested that intensity and distribution of
staining for the EMA-like glycoprotein is of prognostic value
(Wilkinson et al., 1984; Ellis et al., 1987). Most of the breast
epithelial cells in these aspirates fixed in methacarn were
strongly positive for EMA, and it was not possible to deter-
mine whether it was cytoplasmic or membrane in distribu-
tion. Fewer tumours were cytokeratin positive than EMA
positive, although the two EMA negative tumours were posi-
tive for CAM 5.2.
Formalin fixed breast carcinomas are usually positive with
the CAM 5.2 antibody (Makin et al., 1984; and personal
data). In this study, tumour cells in only 54 of the 61 pellets
were cytokeratin positive, but we have previously shown that
CAM 5.2 staining of tissue fixed in methacarn is weaker than
that in adjacent blocks fixed in formalin (Roe et al., 1986).
The method described in this paper for the immunocyto-
chemical demonstration of multiple cell markers in fine
needle aspirates has several advantages over alternative tech-IMMUNOSTAINING PELLETED FNA 633
niques. It avoids problems with the collection and storage of
frozen material, and since the cells are properly fixed and
processed, with good cytological preservation, the slide used
for immunostaining can also be used to confirm the presence
of malignant cells. The variability of tumour cell content
from slide to slide of the same aspirate is a well recognised
problem in cytology. With antibodies requiring unfixed pre-
parations, additional H & E or Giemsa stained slides must be
prepared from the aspirate for diagnosis. These will contain a
different cell population, so decreasing the accuracy of ass-
essment (Coombes et al., 1987). Although some workers have
been able to use the ERICA antibody on paraffin embedded
tissues (Shintaku & Said, 1987), others have met with consis-
tent success only by using unfixed tissue sections or smears
(Millis & Barnes, personal communication).
This technique may equally well be used on pellets fixed in
formalin or in any other appropriate fixative, and for the
immunocytochemical localisation of multiple markers in tu-
mours from other sites. Fine needle aspiration has good
patient acceptability, obviating the need for Tru-cut or sur-
gical biopsy and anaesthesia. Multiple sites can be sampled,
and the procedure repeated during therapy. Fixed cells ob-
tained from fine needle aspirates can be stored either as
paraffin wax blocks or as unstained sections mounted on
glass slides, allowing retrospective as well as prospective
studies, without the need for low temperature storage.
Sections of the pellets can be stained for growth factors
and oncogene products, such as epidermal growth factor
receptor (Sainsbury et al., 1987), and c-erb-B2 (Venter et al.,
1987), whose over-expression has been shown to correlate
with a worse prognosis. Antibodies suitable for immunostain-
ing are already available for some of these, or will become so
in the near future. In addition, now that in situ hybridisation
techniques can be used for the demonstration of DNA and
RNA in fixed tissue sections (Brigati et al., 1983), pelleted
fine needle aspirates can provide archival material for studies
of gene copy number, expression and mRNA content (Prin-
gle et al., 1987).
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